Bausch Health Companies (NYSE:BHC) Upgraded to “Hold” by Evercore ISI

Evercore ISI upgraded shares of Bausch Health Companies (NYSE:BHC) to a hold rating in a research note issued to investors on Tuesday, Zacks.com reports.

Other research analysts have also recently issued research reports about the company. Jefferies Financial Group decreased their price target on Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, August 7th. Scotiabank reduced their target price on Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating on the stock in a report on Friday, August 2nd. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Wednesday, September 25th. Piper Sandler downgraded Bausch Health Companies from a “neutral” rating to an “underweight” rating and lowered their target price for the stock from $9.00 to $3.00 in a research note on Friday, August 2nd. Finally, Truist Financial reduced their price target on shares of Bausch Health Companies from $8.00 to $7.00 and set a “hold” rating on the stock in a research note on Thursday, July 25th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Bausch Health Companies presently has an average rating of “Hold” and a consensus price target of $7.33.

Bausch Health Companies Stock Up 0.9 %

Shares of BHC stock opened at $8.47 on Tuesday. The company has a market capitalization of $3.06 billion, a PE ratio of -6.83 and a beta of 0.77. The firm has a 50 day moving average price of $6.90 and a two-hundred day moving average price of $7.15. Bausch Health Companies has a 12-month low of $3.96 and a 12-month high of $11.46.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.89 by $0.09. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.33 billion. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 742.06%. During the same period in the prior year, the company posted $0.81 earnings per share. As a group, research analysts expect that Bausch Health Companies will post 3.61 EPS for the current year.

Insider Activity

In other Bausch Health Companies news, EVP Seana Carson sold 13,370 shares of Bausch Health Companies stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $6.21, for a total value of $83,027.70. Following the completion of the sale, the executive vice president now directly owns 435,198 shares in the company, valued at approximately $2,702,579.58. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 8.12% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bausch Health Companies

A number of institutional investors and hedge funds have recently bought and sold shares of BHC. Salem Investment Counselors Inc. bought a new stake in shares of Bausch Health Companies during the 1st quarter worth $32,000. CANADA LIFE ASSURANCE Co grew its stake in Bausch Health Companies by 4.1% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 88,457 shares of the company’s stock valued at $933,000 after buying an additional 3,519 shares in the last quarter. Bfsg LLC raised its holdings in Bausch Health Companies by 46.7% during the 2nd quarter. Bfsg LLC now owns 11,450 shares of the company’s stock valued at $80,000 after acquiring an additional 3,643 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Bausch Health Companies by 6.9% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 60,706 shares of the company’s stock worth $423,000 after acquiring an additional 3,923 shares in the last quarter. Finally, Blair William & Co. IL boosted its holdings in shares of Bausch Health Companies by 5.0% in the first quarter. Blair William & Co. IL now owns 84,245 shares of the company’s stock worth $894,000 after acquiring an additional 4,000 shares during the period. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.